The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy

ConditionProstate Cancer

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexMale

Age18+

SponsorSir Mortimer B. Davis - Jewish General Hospital

About this trial

The objective of the study is to evaluate the predictive value of TMPRSS2-ERG gene fusion and PTEN in patients with high risk prostate cancer treated with first line LHRH agonist after biochemical failure.

Eligibility criteria

Qualifiers

T3a +

PSA > 20

Gleason 8 or higher

Karnofsky performance status ≥ 70.

Disqualifiers

None

Trial design

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Locations9

Select a site below to view it on the map.

Sponsors and collaborators

Sir Mortimer B. Davis - Jewish General Hospital

Lead sponsor

Source ClinicalTrials.gov